Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05954559
Other study ID # IRB00396901
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date September 2024
Est. completion date March 2026

Study information

Verified date May 2024
Source Johns Hopkins University
Contact Joao Lima, Professor
Phone 4106141284
Email jlima@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging. The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). However, given its at least twofold higher relaxivity than other GBCAs, the performance of Elucirem in cardiac MR (CMR) has yet to be demonstrated. The hypothesis for the study: Half dose (0.05mmol/kg) Elucirem is not inferior to double dose (0.2 mmol/kg) Dotarem in the myocardial scar assessment. All participants will be selected from the investigators previous CMR study cohort with double-dose Dotarem T1 mapping and LGE images. Ten participants without scars will be recruited for the Phase I dose evaluation. Five for 0.05 mmol/kg and five for 0.075 mmol/kg. The investigators have identified 15 participants with LGE findings from double-dose Dotarem CMR acquired in the years 2021, 2022, or earlier years. This study was performed in August 2022. The same protocol will be used for single-dose Elucirem.


Description:

Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging. The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). Based on the investigators previous experience with 0.2 mmol/kg Dotarem, the optimal post-contrast T1 for LGE was when the remote myocardium (i.e. area without scar) had T1 of around 400ms at 12 mins post-contrast. The investigators hypothesize that with 0.05 mmol/kg Elucirem, post T1 will recover to 400 ms faster than 12 minutes after injection. It will likely be between 6 to 10 minutes post-contrast. A serial of T1 mapping will provide the information for timing. However, if myocardial T1 were not reduced short enough or recovers to 400 ms in less than 5 minutes post-contrast with 0.05 mmol/kg Elucirem, that is a sign of inadequate dose. Same evaluation will be performed for 0.075 mmol/kg Elucirem. The investigators hypothesize that if 0.05 mmol/kg falls short, 0.075 mmol/kg should be adequate. Since a single dose (0.1 mmol/kg) of Dotarem is proved to be adequate for LGE in many literatures, less Elucirem should be used to demonstrate its benefit. Study Procedure: It is a non-randomized cohort study. Participants with precious double dose Dotarem CMR will be recruited. The study has two phases. Phase I is to evaluate the optimal dose, 0.05 mmol/kg (N=5) or 0.075 mmol/kg (N=5) by assessing a serial of the myocardial T1 mapping in normal volunteers. T1 mapping will be acquired every 2.5 minutes after injection to 25 minutes post-contrast. Based on the results of Phase I, the optimal dose will be used in the Phase II scar assessment in patients with a scar from a previous double-dose Dotarem study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date March 2026
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Participants from previous double-dose Doatrem CMR study who are willing to participate and sign the consent will be enrolled in this study. Participants must be =21 years old, less than 120kg, not claustrophobic, and eGFR be 60 and more. Exclusion Criteria: - Participants under 21 years old will be excluded. Contraindications or limitations to contrast-enhanced MRI such as self-report of kidney disease, including kidney transplant or kidney surgery, eGFR less than 60, Metal fragments in eyes, brain, or spinal cord, Internal electrical devices such as cochlear implant, spinal cord stimulator, pacemaker, or defibrillator, pregnancy, allergic reaction to gadolinium in the past, claustrophobia, and cardiogenic shock or unstable condition that cannot tolerate the MRI scan will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Elucirem (Gadopiclenol)
Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.

Locations

Country Name City State
United States Johns Hopkins School of Medicine Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Guerbet

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Non-inferiority of half dose of Elucirem to double dose Dotarem Half dose (0.05mmol/kg) Elucirem is not inferior to double dose (0.2 mmol/kg) Dotarem in the myocardial scar assessment. 1-2 years
Secondary Post-contrast T1 values Post-contrast T1 values will be measured. 1-2 years
Secondary late gadolinium enhancement (LGE), late gadolinium enhancement (LGE) will be measured. 1-2 years
Secondary Extracellular volume fraction (ECV) Extracellular volume fraction (ECV) will be measured. 1-2 years
See also
  Status Clinical Trial Phase
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT03176862 - Left Ventricular Fibrosis in Chronic Kidney Disease N/A
Recruiting NCT06039969 - Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.
Not yet recruiting NCT06059287 - The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics N/A
Completed NCT00879060 - Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Phase 4
Completed NCT02834104 - Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers N/A
Active, not recruiting NCT04444128 - IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Recruiting NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT02428374 - Role of Immune Responses After Acute Myocardial Infarction Phase 4
Recruiting NCT05867589 - Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases N/A
Not yet recruiting NCT06326970 - SPECT Fibroblast Activation Protein Imaging in Patients With Cardiac Disease
Completed NCT02432885 - Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial Phase 3
Completed NCT04397198 - The Assessment Of Myocardial Viability Based On CTA/MRI Hybrid Models
Recruiting NCT03405987 - Association of T1-mapping and LV Strain Analysis by CMR
Completed NCT01160471 - Noninvasive Imaging of Heart Failure: A Pilot Study
Completed NCT03422770 - Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis N/A
Not yet recruiting NCT03515291 - A Trial of Cardiac Injections of iMP Cells During CABG Surgery Phase 2
Recruiting NCT02670031 - Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Terminated NCT02012725 - Molecular MRI of the Fibrotic Heart N/A
Completed NCT02727725 - An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images N/A